ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
All resolutions were approved and 35% of the issued shares represented.
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the voting results from its Annual General Meeting (AGM) of Shareholders held on Monday, June 26, 2023, in Madrid. A total of 20.009.878 of the issued and outstanding common shares of the Corporation (35,01%) were represented either in person or by proxy at the meeting.
The shareholders of the Company approved all resolutions listed below, as proposed by the Board of Directors at the Company's Annual General Meeting, with favorable votes ranging from 90% to 96%.
- The annual report and the financial statements for the year 2022.
- The appropriation of loss.
- The discharge of the members of the Board of Directors.
- Re-election of the Audit Firm (Deloitte SL).
- Modification of the Company's Bylaws to include approval of “Loyalty Shares”.
- Approval of a Long-Term Incentive Plan within the Directors' Remuneration Policy.
- Customary delegations to formalize and notarize the resolutions.
- The compensation for the members of the Board of Directors for the fiscal year 2022
Full details of the resolutions and their independent item voting results may be examined on the Company’s web page and on the Market Regulator’s (CNMV) web page as Other Relevant Information.